Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.42 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.41 |
| ▸ | WNT3A | P56704 | 3/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 2/20 | 0.39 |
| ▸ | NOS2 | P35228 | 2/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | IDE | P14735 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7009852 | 0.89 | AGTR2 (0.42) | AOC3AGTR2WNT3ACHRM4MAPK1 | |
| SCHEMBL7016082 | 0.80 | NPSR1 (0.46) | MAPTALDH1A1LMNACHRM4KDM4E | |
| SCHEMBL7010020 | 0.78 | SIGMAR1 (0.46) | — | |
| SCHEMBL7015734 | 0.78 | NR1H2 (0.46) | AOC3WNT3ACHRM4MAPK1F10 | |
| SCHEMBL7016352 | 0.76 | SIGMAR1 (0.45) | — | |
| SCHEMBL7013012 | 0.76 | AOC3 (0.39) | AOC3AGTR2CHRM4MAPK1F10 | |
| SCHEMBL7013241 | 0.75 | SIGMAR1 (0.42) | — | |
| SCHEMBL7020197 | 0.73 | SIGMAR1 (0.42) | — | |
| SCHEMBL29973124 | 0.73 | CHRM4 (0.54) | AOC3CHRM4MAPK1F10 | |
| SCHEMBL7016361 | 0.73 | LGMN (0.61) | MAPTALDH1A1LMNAMAPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1302462-A1 | SULFONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | SULT1E1, RRS1, SHH | MAPT 4719/4885ALDH1A1 4317/4885LMNA 3485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.